Total Payments
$98,246
2024 Payments
$9,279
Companies
20
Transactions
118
Medicare Patients
15,160
Medicare Billing
$277,198
Payment Breakdown by Category
Consulting$63,830 (65.0%)
Other$28,089 (28.6%)
Food & Beverage$4,011 (4.1%)
Travel$2,260 (2.3%)
Research$54.15 (0.1%)
Education$2.25 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $63,830 | 16 | 65.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,089 | 14 | 28.6% |
| Food and Beverage | $4,011 | 74 | 4.1% |
| Travel and Lodging | $2,260 | 12 | 2.3% |
| Unspecified | $54.15 | 1 | 0.1% |
| Education | $2.25 | 1 | 0.0% |
Payments by Type
General
$98,192
117 transactions
Research
$54.15
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $38,541 | 51 | $0 (2024) |
| Novo Nordisk Inc | $21,624 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $11,010 | 9 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $9,115 | 3 | $0 (2022) |
| Merck Sharp & Dohme LLC | $9,005 | 6 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $3,912 | 4 | $0 (2020) |
| Esperion Therapeutics, Inc. | $3,768 | 11 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $546.03 | 6 | $0 (2024) |
| HeartFlow, Inc. | $139.43 | 1 | $0 (2022) |
| Kaneka Medical America LLC | $121.02 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,279 | 23 | Merck Sharp & Dohme LLC ($6,007) |
| 2023 | $664.58 | 15 | Novo Nordisk Inc ($292.98) |
| 2022 | $27,822 | 23 | Amgen Inc. ($9,478) |
| 2021 | $38,482 | 26 | Novo Nordisk Inc ($20,813) |
| 2020 | $19,285 | 18 | Amgen Inc. ($12,238) |
| 2019 | $418.17 | 8 | Regeneron Healthcare Solutions, Inc. ($189.31) |
| 2018 | $2,111 | 3 | Regeneron Pharmaceuticals, Inc. ($2,090) |
| 2017 | $184.34 | 2 | Regeneron Healthcare Solutions, Inc. ($130.19) |
All Payment Transactions
118 individual payment records from CMS Open Payments — Page 4 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/29/2021 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $8,437.50 | General |
| 03/12/2021 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 03/10/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Cardiology | ||||||
| 03/02/2021 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 03/02/2021 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $467.00 | General |
| Category: Cardiology | ||||||
| 02/25/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $115.79 | General |
| Category: Cardiology | ||||||
| 02/16/2021 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 02/16/2021 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $467.00 | General |
| Category: Cardiology | ||||||
| 02/10/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Cardiology | ||||||
| 02/09/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $11.67 | General |
| Category: Cardiology | ||||||
| 02/01/2021 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $6,375.00 | General |
| 01/05/2021 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,401.00 | General |
| Category: Cardiology | ||||||
| 12/15/2020 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 12/15/2020 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $467.00 | General |
| Category: Cardiology | ||||||
| 12/10/2020 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Cardiology | ||||||
| 11/07/2020 | Novartis Pharmaceuticals Corporation | PELACARSEN (Drug) | Consulting Fee | Cash or cash equivalent | $2,720.00 | General |
| 10/23/2020 | Novartis Pharmaceuticals Corporation | PELACARSEN (Drug) | Consulting Fee | Cash or cash equivalent | $2,560.00 | General |
| 03/13/2020 | Amgen Inc. | EVENITY (Biological), Prolia, Repatha | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| Category: Bone Health | ||||||
| 03/13/2020 | Amgen Inc. | EVENITY (Biological), Prolia, Repatha | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Bone Health | ||||||
| 02/22/2020 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $129.11 | General |
| 02/22/2020 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $45.05 | General |
| 02/22/2020 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $25.99 | General |
| 02/22/2020 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $23.12 | General |
| 02/21/2020 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $476.71 | General |
| 02/21/2020 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $325.66 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| HEALTH ECONOMICS OUTCOME RESEARCH RELATED TO PRALUENT | Regeneron Pharmaceuticals, Inc. | $54.15 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 3,135 | 4,118 | $360,343 | $61,881 |
| 2022 | 9 | 3,795 | 4,978 | $424,354 | $69,143 |
| 2021 | 8 | 4,205 | 5,750 | $479,993 | $81,151 |
| 2020 | 10 | 4,025 | 5,879 | $392,064 | $65,023 |
Total Patients
15,160
Total Services
20,725
Medicare Billing
$277,198
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 152 | 215 | $67,510 | $20,541 | 30.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 2,231 | 3,093 | $154,650 | $19,183 | 12.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 599 | 639 | $80,514 | $6,714 | 8.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $24,633 | $6,494 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 62 | $13,144 | $3,335 | 25.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 34 | $10,268 | $3,195 | 31.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 24 | $9,624 | $2,420 | 25.1% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 2,675 | 3,741 | $187,050 | $23,505 | 12.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 118 | 145 | $45,530 | $14,393 | 31.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 74 | 74 | $35,742 | $9,141 | 25.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 752 | 812 | $102,312 | $8,112 | 7.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 80 | 95 | $20,140 | $5,794 | 28.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 42 | $12,684 | $3,410 | 26.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 25 | 25 | $10,025 | $2,631 | 26.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 29 | 29 | $9,193 | $1,829 | 19.9% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2022 | 15 | 15 | $1,678 | $328.23 | 19.6% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 2,950 | 4,340 | $217,000 | $29,168 | 13.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 95 | 95 | $45,885 | $12,357 | 26.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 82 | 113 | $35,482 | $11,581 | 32.6% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 891 | 962 | $121,212 | $10,371 | 8.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 86 | 109 | $23,108 | $7,704 | 33.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 44 | 74 | $22,348 | $6,154 | 27.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 17 | 17 | $6,817 | $1,925 | 28.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 23 | 23 | $7,291 | $1,806 | 24.8% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Office | 2021 | 17 | 17 | $850.00 | $85.63 | 10.1% |
About Khurram Nasir, MD, MPH
Khurram Nasir, MD, MPH is a Cardiovascular Disease healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2009. The National Provider Identifier (NPI) number assigned to this provider is 1861629818.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Khurram Nasir, MD, MPH has received a total of $98,246 in payments from pharmaceutical and medical device companies, with $9,279 received in 2024. These payments were reported across 118 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($63,830).
As a Medicare-enrolled provider, Nasir has provided services to 15,160 Medicare beneficiaries, totaling 20,725 services with total Medicare billing of $277,198. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location New Haven, CT
- Active Since 06/17/2009
- Last Updated 06/12/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1861629818
Products in Payments
- Repatha (Biological) $29,297
- LEQVIO (Drug) $5,730
- EVENITY (Biological) $5,500
- PELACARSEN (Drug) $5,280
- ELIQUIS (Drug) $5,080
- NEXLIZET (Drug) $3,588
- PRALUENT ALIROCUMAB INJECTION (Biological) $2,274
- PRALUENT (Biological) $1,957
- Ozempic (Drug) $658.61
- EVKEEZA (Biological) $226.53
- NEXLETOL (Drug) $180.07
- FFRct (Device) $139.43
- PREVELEAK (Device) $107.36
- PRALUENT (Drug) $92.61
- LifeVest (Device) $63.29
- VYNDAQEL (Drug) $43.81
- Flexitouch Plus (Device) $39.83
- Wegovy (Drug) $28.83
- OPTIMIZER (Device) $26.40
- CARDIOMEMS (Device) $22.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New Haven
Dr. Jeffrey Testani, M.d, M.D
Cardiovascular Disease — Payments: $625,767
Cardiovascular Disease $625,767
Henry Ward, M.d, M.D
Cardiovascular Disease — Payments: $404,260
Cardiovascular Disease $404,260
Dr. John Forrest, M.d, M.D
Cardiovascular Disease — Payments: $232,147
Cardiovascular Disease $232,147
Dr. Alexandra Lansky, Md, MD
Cardiovascular Disease — Payments: $205,439
Cardiovascular Disease $205,439
Dr. Hyung Chun, Md, MD
Cardiovascular Disease — Payments: $180,221
Cardiovascular Disease $180,221
Lissa Sugeng, Md, Mph, MD, MPH
Cardiovascular Disease — Payments: $106,815
Cardiovascular Disease $106,815